SCHEMBL104760 — predicted protein targets

Predicted protein targets (top 20)

	gene	UniProt	supporting neighbours	confidence
▸	MET	P08581	19/20	0.78

▸	KDR	P35968	18/20	0.78

▸	AXL	P30530	2/20	0.78

▸	FLT3	P36888	2/20	0.78

▸	MST1R	Q04912	2/20	0.78

▸	PLK4	O00444	1/20	0.78

▸	MAP4K4	O95819	1/20	0.78

▸	ABL1	P00519	1/20	0.78

▸	LCK	P06239	1/20	0.78

▸	FYN	P06241	1/20	0.78

▸	LYN	P07948	1/20	0.78

▸	HCK	P08631	1/20	0.78

▸	PDGFRB	P09619	1/20	0.78

▸	BCR	P11274	1/20	0.78

▸	SRC	P12931	1/20	0.78

▸	ABL2	P42684	1/20	0.78

▸	FRK	P42685	1/20	0.78

▸	SYK	P43405	1/20	0.78

▸	DDR1	Q08345	1/20	0.78

▸	MERTK	Q12866	1/20	0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL13926830	0.94	MET (0.75)	METKDRAXLFLT3MST1R
SCHEMBL2670902	0.94	MET (0.75)	METKDRAXLFLT3MST1R
Glesatinib SCHEMBL29351360	0.88	MET (1.00)	METKDRAXLFLT3MST1R
Glesatinib SCHEMBL106319	0.88	MET (1.00)	METKDRAXLFLT3MST1R
SCHEMBL103919	0.88	MET (0.61)	METKDRAXLFLT3MST1R
SCHEMBL2670909	0.86	MET (0.70)	METKDRAXLFLT3MST1R
SCHEMBL104761	0.85	MET (0.69)	METKDRAXLFLT3MST1R
SCHEMBL169907	0.85	KDR (0.58)	METKDRAXLFLT3MST1R
SCHEMBL10172980	0.85	AXL (0.81)	METKDRAXLFLT3MST1R
SCHEMBL2670515	0.84	MET (0.89)	METKDRAXLFLT3MST1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-2426108-B1	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	METHYLGENE INC (CA)	2016-08-10	—	—	EP	disclosed
EP-2426108-B1	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	METHYLGENE INC (CA)	2016-08-10	—	—	EP	disclosed
US-9018378-B2	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	METHYLGENE INC. (CA)	2015-04-28	—	—	US	disclosed
US-9018378-B2	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	METHYLGENE INC. (CA)	2015-04-28	—	—	US	disclosed
US-8907091-B2	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	METHYLGENE INC. (CA)	2014-12-09	—	—	US	disclosed
US-8907091-B2	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	METHYLGENE INC. (CA)	2014-12-09	—	—	US	disclosed
US-8907091-B2	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	METHYLGENE INC. (CA)	2014-12-09	—	—	US	disclosed
US-8846927-B2	Inhibitors of protein tyrosine kinase activity	METHYLGENE INC. (CA)	2014-09-30	—	—	US	disclosed
US-8846927-B2	Inhibitors of protein tyrosine kinase activity	METHYLGENE INC. (CA)	2014-09-30	—	—	US	disclosed
US-20130310564-A1	Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors	METHYLGENE INC. (CA)	2013-11-21	—	—	US	disclosed
US-20120108628-A1	INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY	Mirati Therapeutics, Inc.	2012-05-03	—	—	US	disclosed
US-20120095234-A1	PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS	Mirati Therapeutics, Inc.	2012-04-19	—	—	US	disclosed
US-20120095234-A1	PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS	Mirati Therapeutics, Inc.	2012-04-19	—	—	US	disclosed
EP-2426108-A1	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	MethylGene Inc. (CA)	2012-03-07	—	—	EP	disclosed
US-20090286984-A1	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	Mirati Therapeutics, Inc.	2009-11-19	—	—	US	disclosed
US-20090286984-A1	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	Mirati Therapeutics, Inc.	2009-11-19	—	—	US	disclosed
US-20090286984-A1	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	Mirati Therapeutics, Inc.	2009-11-19	—	—	US	disclosed
US-20090264440-A1	INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY	Mirati Therapeutics, Inc.	2009-10-22	—	—	US	disclosed
US-20090264440-A1	INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY	Mirati Therapeutics, Inc.	2009-10-22	—	—	US	disclosed
WO-2009026717-A1	INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY	METHYLGENE INC. (CA)	2009-03-05	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20120095234-A1	PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS	MAP3K19, MAP3K9, MAP4K2	MET 1062/4885KDR 526/4885AXL 418/4885
US-20130310564-A1	Processes and Intermediates for Preparing Fused Heterocyclic Kinase Inhibitors	MAP3K19, MAP3K15, MAP3K9	MET 916/4885KDR 535/4885AXL 375/4885
US-20090286984-A1	Processes and intermediates for preparing fused heterocyclic kinase inhibitors	MAP3K19, MAP3K9, MAP4K2	MET 1062/4885KDR 526/4885AXL 418/4885
US-20090264440-A1	INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY	HGF, ERBB2, MET	MET 3/4885KDR 11/4885AXL 130/4885
US-20120108628-A1	INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY	HGF, ERBB2, MET	MET 3/4885KDR 11/4885AXL 130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.